Equels Thomas K
CIK 0001450324
CEO & PresidentDirector
Filings
28
Latest Mar 16, 2026
Issuers covered
1
Showing
28 of 28
Page 1
Track record
21 of 21 open-market trades scored (100% price coverage). Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 21 | 33% | +13.2% | 0.0% | +233.3% | -30.8% |
| 90 days | 21 | 19% | -14.6% | -30.0% | +212.0% | -69.1% |
| 180 days | 21 | 5% | -42.3% | -55.0% | +109.4% | -82.2% |
| 365 days | 19 | 5% | -69.3% | -91.5% | +50.0% | -94.9% |
Issuers
Companies where Equels Thomas K has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| AIM | Aim Immunotech Inc. | 28 | Mar 16, 2026 |
All filings
28 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|